
Yokneam, Isr?l-China's regulatory agency for medical devices approved Lumenis to market Selecta II Selective Laser Trabeculoplasty (SLT) technology for treatment of glaucoma. The device reduces IOP associated with glaucoma. The key aspect of Selecta II is that medications are not required postoperatively.